M. Kulyk & Associates LLC Acquires 1,620 Shares of Becton, Dickinson and Company (NYSE:BDX)

M. Kulyk & Associates LLC raised its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 5.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 31,062 shares of the medical instruments supplier's stock after acquiring an additional 1,620 shares during the period. Becton, Dickinson and Company comprises about 1.6% of M. Kulyk & Associates LLC's investment portfolio, making the stock its 20th largest holding. M. Kulyk & Associates LLC's holdings in Becton, Dickinson and Company were worth $7,115,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of BDX. Smallwood Wealth Investment Management LLC acquired a new position in shares of Becton, Dickinson and Company during the first quarter worth about $27,000. REAP Financial Group LLC raised its holdings in Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 55 shares in the last quarter. Alpine Bank Wealth Management bought a new stake in Becton, Dickinson and Company during the first quarter worth about $29,000. Cornerstone Planning Group LLC raised its holdings in Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 99 shares in the last quarter. Finally, Nexus Investment Management ULC bought a new stake in Becton, Dickinson and Company during the first quarter worth about $34,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. The Goldman Sachs Group lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 target price on the stock. in a report on Friday, May 2nd. Piper Sandler lowered Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $260.00 to $185.00 in a research note on Friday, May 2nd. Barclays dropped their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Wall Street Zen lowered Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Finally, Wells Fargo & Company lowered Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research note on Thursday, May 1st. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus target price of $219.22.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares of the company's stock, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David Shan sold 1,166 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president directly owned 4,575 shares of the company's stock, valued at $783,194.25. This trade represents a 20.31% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of BDX traded up $1.04 during mid-day trading on Thursday, reaching $183.62. 1,801,449 shares of the stock traded hands, compared to its average volume of 2,647,861. The firm has a fifty day moving average price of $173.87 and a 200 day moving average price of $203.40. The company has a market cap of $52.63 billion, a price-to-earnings ratio of 35.04, a price-to-earnings-growth ratio of 1.37 and a beta of 0.25. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the business posted $3.17 earnings per share. Becton, Dickinson and Company's revenue for the quarter was up 4.5% on a year-over-year basis. As a group, equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.27%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is 79.39%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.